TRAF5 Antibody (E-8): sc-271144

TRAF5 Antibody (E-8) is a mouse monoclonal IgG3 antibody that detects TRAF5 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TRAF5 is a crucial member of the TNF receptor-associated factor (TRAF) protein family, which plays a significant role in mediating signal transduction from the tumor necrosis factor (TNF) receptor superfamily. TRAF5 is primarily located in the cytoplasm, where TRAF5 forms complexes with various receptors, including CD40, CD27, and CD30, facilitating essential signaling pathways that lead to the activation of NF-kappa B and the regulation of cell survival. Proper functioning of TRAF5 is vital for processes such as osteoclastogenesis, as TRAF5 influences the differentiation and activity of osteoclasts, which are essential for bone remodeling. Additionally, TRAF5 undergoes post-translational modifications, including ubiquitination, which can affect stability and interaction with other signaling molecules, thereby modulating activity in immune responses. Anti-TRAF5 antibody (E-8) is an invaluable tool for researchers studying the intricate signaling networks involved in immune regulation and cell survival.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TRAF5 Antibody (E-8) References:

1. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis.  |  Kanazawa, K., et al. 2003. J Bone Miner Res. 18: 443-50. PMID: 12619928
2. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling.  |  Tang, ED. and Wang, CY. 2010. PLoS One. 5: e9172. PMID: 20161788
3. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.  |  Gao, L., et al. 2016. J Hepatol. 65: 125-136. PMID: 27032381
4. miR-135a suppresses migration of gastric cancer cells by targeting TRAF5-mediated NF-κB activation.  |  Xie, Y., et al. 2019. Onco Targets Ther. 12: 975-984. PMID: 30774383
5. Upregulation of miR-29b-3p protects cardiomyocytes from hypoxia-induced apoptosis by targeting TRAF5.  |  Cai, Y. and Li, Y. 2019. Cell Mol Biol Lett. 24: 27. PMID: 31011336
6. miR-141-3p and TRAF5 Network Contributes to the Progression of T-Cell Acute Lymphoblastic Leukemia.  |  Zhou, R., et al. 2019. Cell Transplant. 28: 59S-65S. PMID: 31722554
7. Circ_0010729 regulates hypoxia-induced cardiomyocyte injuries by activating TRAF5 via sponging miR-27a-3p.  |  Lei, D., et al. 2020. Life Sci. 262: 118511. PMID: 33010282
8. Association of methylation level and transcript level in TRAF5 gene with ankylosing spondylitis: a case-control study.  |  Xu, S., et al. 2021. Genes Immun. 22: 101-107. PMID: 34021268
9. MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.  |  Wu, S., et al. 2021. Eur J Histochem. 65: PMID: 34155879
10. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.  |  Ishida, TK., et al. 1996. Proc Natl Acad Sci U S A. 93: 9437-42. PMID: 8790348

The preferred TRAF5 antibody is TRAF5 Antibody (E-4): sc-74502.